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Abstract Clinical guidelines that rely on observational data
due to the absence of data from randomized trials benefit when
the observational data or its analysis emulates trial data or its
analysis. In this paper, we review a methodology for emulat-
ing trials that compare the effects of different timing strategies,
that is, strategies that vary the frequency of delivery of a med-
ical intervention or procedure. We review trial emulation for
comparing (i) single applications of the procedure at different
times, (ii) fixed schedules of application, and (iii) schedules
adapted to the evolving clinical characteristics of the patients.
For illustration, we describe an application in which we esti-
mate the effect of surveillance colonoscopies in patients who
had an adenoma detected during the Norwegian Colorectal
Cancer Prevention (NORCCAP) trial.
Keywords Causal inference . Dynamic strategies . Inverse
probability weighting . Colorectal cancer . Surveillance .
Colonoscopy
Introduction
Clinical decisions are increasingly reliant on guidelines, but
clinical guidelines are only as good as the available evidence
on the comparative effectiveness of interventions [1•]. Ideally,
such evidence would come from randomized controlled trials.
When a randomized trial is not available, it may be possible to
emulate it using observational data [2•]. This approach re-
quires appropriate confounding adjustment, avoidance of se-
lection bias in the definition of the groups to be compared, and
formulation of a research question that is relevant for decision
makers.
Prior explicit attempts to emulate trials using observational
data have studied, for example, postmenopausal hormone
therapy [3], statins [4••], epoetin [5••], and antiretroviral ther-
apy [6••]. Here, we review the emulation of trials to compare
strategies that differ in the timing of the intervention of inter-
est. As an example, we will consider post-polypectomy sur-
veillance by colonoscopy. During this procedure, adenomas
(benign tumors of the colon [7]) are detected and removed.
Most adenomas will not develop into colorectal cancer, but
most cancers arise from adenomas [8]. In patients with re-
moved adenomas, surveillance colonoscopies are recom-
mended to detect and remove future adenomas before they
become malignant. The optimal interval between colonosco-
pies is not known. Current guidelines both in the USA [9] and
the EU [10] are mostly based on expert opinion due to the
scarcity of available evidence.
Besides reviewing a methodology to emulate trials for the
comparison of strategies that administer the same intervention
at different times, we also review a classification of these
strategies. First, we consider point interventions to study the
effectiveness of a single application of the treatment. Second,
we consider sustained interventions to study the effectiveness
of a fixed treatment schedule (e.g., colonoscopy at 3 years
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after the initial procedure). Third, we consider sustained inter-
ventions to study the effectiveness of a personalized schedule
of treatment (e.g., colonoscopy every year if the most recent
procedure detected large adenomas, otherwise every 3 years).
To fix ideas, we review the methodology in the context of its
implementation to a cohort of Norwegian individuals.We start
by describing this cohort.
Data
The Norwegian Colorectal Cancer Prevention (NORCCAP)
screening study was a randomized clinical trial of once-only
sigmoidoscopy screening versus no sigmoidoscopy, conducted
in Oslo and Telemark counties in Norway between 1999 and
2001. Our analysis includes participants in the sigmoidoscopy
arm in whom at least one adenoma was detected (n=2190). As
part of the trial, endoscopies were conducted in these individ-
uals until the bowel was free from adenomas. We excluded
patients with history of serious gastrointestinal disease, known
genetic predisposition to colorectal cancer, and cancer detected
as a result of screening in NORCCAP.
In addition to the available data (age, sex, county, smoking,
family history of colorectal cancer, and findings at
NORCCAP colonoscopies), we conducted a manual chart re-
view at all hospitals in Oslo and Telemark—guided by claims
data from the governmental single-payer agency HELFO—to
collect data on the date, findings (e.g., size and type of adeno-
mas) and indication of all subsequent colonoscopies and sig-
moidoscopies. Of the post-screening endoscopies, 64 % were
for surveillance purposes (3 % sigmoidoscopies and 61 %
colonoscopies); 30 % were clinically indicated because of
symptoms (27 % colonoscopies, 3 % sigmoidoscopies); and
6 % were due to a recent incomplete endoscopy (4 % colo-
noscopies, 2 % sigmoidoscopies).
Our outcome of interest was incidence of colorectal cancer.
For many surveillance interventions, the use of cancer inci-
dence as an outcome is questionable because of potential lead
time bias: [11] cancer cases will be detected earlier in patients
with more intensive surveillance, which will make surveil-
lance appear less beneficial. In this case, however, the use of
the outcome cancer incidence is justified because most of the
beneficial effect of surveillance colonoscopy seems to be due
to removing adenomas before they become malignant [12],
with only a small component of the effect due to earlier de-
tection of prevalent cancer. Death from colorectal cancer
could not be studied as an outcome because there were too
few cases.
We refer to the date of the last NORCCAP colonoscopy as
time of Bfirst eligibility^ for our analyses. For each individual,
follow-up ends at colorectal cancer, death, sigmoidoscopy,
emigration, or December 2011, whichever occurred first. Be-
cause we are trying to estimate the effects of post-baseline
colonoscopies, which were not randomly assigned to the trial
participants, ours is an analysis of observational data. The
flow chart in Fig. 1 describes the enrollment of participants
in our study. Table 1 displays the characteristics of the eligible
individuals.
Three Hypothetical Randomized Trials
The design of any trial is determined by the causal question of
interest, which in turn is determined by the population, the
strategies being compared, and the outcome of interest to the
decision makers [13]. For surveillance tests, the strategies are
defined by the timing of the test. Some strategies involve a
point intervention at baseline, whereas other strategies involve
interventions that are sustained over time according to either a
fixed schedule (e.g., do not perform a colonoscopy for 5 years
after baseline, then perform a colonoscopy at the end of year
5) or a schedule that depends on each individual’s time-
evolving clinical characteristics (i.e., schedule the time of ev-
ery colonoscopy according to the findings at the previous
colonoscopy). We refer to sustained strategies with a fixed
schedule as static and to those with a subject-specific schedule
as dynamic.
Here, we review three types of hypothetical trials that
compare static and dynamic strategies and therefore ad-
dress different questions regarding the effectiveness of sur-
veillance colonoscopy. In all trials, eligible individuals are
followed until death, loss to follow-up (i.e., emigration out
of Norway), sigmoidoscopy, occurrence of the outcome
(here, diagnosis of colorectal cancer), or December 31,
2011, whichever occurred earlier. In all trials, individuals
receive a colonoscopy whenever it is clinically indicated
(e.g., due to symptoms) but a surveillance colonoscopy on-
ly according to the trial protocol. A graphical representation
of each trial is shown in Fig. 2.
Trial type #1: point interventions assigned at a fixed time
after first eligibility
Individuals who survived 36 months since first eligibility are
randomized to either (1) immediate surveillance colonoscopy
or (2) no surveillance colonoscopy. Additional eligibility
criteria are no colorectal cancer, colonoscopy, or sigmoidos-
copy during the 36 months before randomization. Individuals
who reach age 70 or develop any invasive non-colorectal can-
cer before baseline also become ineligible (other comorbidi-
ties might be added to the exclusion criteria). For each indi-
vidual, follow-up starts at the time of randomization, i.e., base-
line is 36 months after first eligibility.
More generally, one can consider trials in which baseline is
month z, where z ranges between 36 and 84. The effect esti-
mates from these trials will only apply to survivors without
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symptoms or cancer by z months after first eligibility. These
trials will help determine the effect of undergoing a colonos-
copy among the survivors, but it does not directly inform the
decision of when to undergo the colonoscopy. The next trial
does so.
Trial type #2: sustained static strategies assigned at first
eligibility
Baseline is the time of first eligibility. Individuals are random-
ized to either (1) surveillance colonoscopy 36 months after
baseline or (2) surveillance colonoscopy 84months after base-
line. Individuals in both arms who reach age 70 or develop
malignancies other than colorectal cancer may have surveil-
lance colonoscopies at any time as determined by their physi-
cian. More generally, one can consider additional arms in
which 36 is replaced by any value of x between 36 and 84.
We could also consider similar trials in which baseline is any
month after first eligibility. For example, one could consider a
trial in which individuals who have survived 36 months after
first eligibility are randomized to either (1) immediate surveil-
lance colonoscopy or (2) surveillance colonoscopy at month
84 after first eligibility (48months after baseline at 36months).
We will only consider trials with baseline at first eligibility.
100210 NORCCAP
participants
Sigmoidoscopy in
1999-2001:
n=20572
Adenomas Detected
in 2211 individuals
Cancer detected
In 41 individuals
No adenoma or
cancer detected in
18320 individuals
2190 individuals met
eligibility criteria
21 did not meet
eligibility criteria:
1987 were cancer
free and alive in
2011:
21 had a diagnosis
of colon cancer by
2011
182 deaths from
other causes by
2011:
Fig. 1 Flowchart of selection of
the 2190 eligible individuals from
the intervention arm of the
NORCCAP trial
Table 1 Characteristics of 2190 eligible individuals from the
intervention arm of the NORCCAP trial
Number of men 1322 (60 %)
Average (SD) age at first eligibility, years 57.2 (3.8)
Median (IQR) duration of follow-up, months 134 (126–143)
Incident cases of colorectal cancer 21
Detected at surveillance colonoscopy 1
Deaths 187
From colorectal cancer 5
Number of colonoscopies during follow-up 819
Number of sigmoidoscopies 75
Number of people with at least one colonoscopy
after first eligibility
577
Number of people whose first follow-up colonoscopy
was for surveillance
395
Median (IQR) time to first follow-up colonoscopy,
months
68 (51–91)
Number of colonoscopies per individual
0 1613 (74 %)
1 389 (18 %)
2 140 (6 %)
3+ 48 (2 %)
Curr Epidemiol Rep (2015) 2:149–161 151
Both trial types #1 and #2 compare fixed surveillance sche-
dules, but they address different questions. Trial #1 helps indi-
viduals who have survived z months after adenoma removal
decide whether they should undergo a surveillance colonoscopy
at that time. Trial #2 helps individuals who just had their adeno-
mas removed decide how long they should wait before having a
surveillance colonoscopy (if they plan to have only one surveil-
lance colonoscopy). Neither trial type considers strategies that
assign different surveillance schedules to different individuals
(i.e., dynamic strategies). The next trial type does so.
Trial type #3: sustained dynamic strategies assigned
at first eligibility
Individuals at first eligibility are randomized to either (1) re-
ceive surveillance colonoscopies according to the following
rules:
& First surveillance colonoscopy at 36 months if the
adenomas detected at baseline sigmoidoscopy were
low risk (1 or 2 small adenomas without villous fea-
tures) and 12months earlier (at month 24) otherwise.
& Follow-up surveillance colonoscopy 36 months after
the previous colonoscopy (surveillance or clinical) if
low-risk adenomas were detected, 12 months earlier
(24 months after the previous colonoscopy) if high-
risk adenomas (more than two, or large, or containing
villous features) were detected, and 12 months later
(48 months) if no adenomas were detected.
or (2) surveillance colonoscopies according to similar rules,
but where 36 months is replaced by 84 months. During the
follow-up, individuals in both arms of the trial may also re-
ceive a colonoscopy whenever it is clinically indicated due to
symptoms. Individuals who reach age 70 or develop malig-
nancies other than colorectal cancer after baseline may have
surveillance colonoscopies at any time as determined by their
physician. For each individual, follow-up starts at the time of
randomization, i.e., baseline is the time of first eligibility.
More generally, one can consider additional arms in which
36 is replaced by x with x ranging from 36 to 84, or trials in
which the time until the next surveillance colonoscopy is ob-
tained by adding or subtracting y (rather than 12) months.
Emulating the Design of the Hypothetical Trials
In this section, we review how to emulate the design of each of
the above hypothetical trials by setting up a database with the
same structure as that of the trial. In the next section, we
review how to mimic the analysis of the hypothetical trials.
Trial type #1: point intervention assigned at a fixed time
after first eligibility
We emulated 49 Btrials,^ one starting at each month z between
months 36 and 84 after first eligibility. For the Btrial^ starting
in month z, we identified the individuals who met the eligibil-
ity criteria at baseline, i.e., all individuals with adenomas
Type 1
Type 3
Time
Type 2
Intervenon
Same  as above, but for x2
Intervenons at subject-speciﬁc mes, depending on evolving covariate history and x1
Intervenon
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Fig. 2 The three trial types
considered in this paper. Circles
represent randomization, dotted
lines represent periods when the
strategy specifies all interventions
(e.g., colonoscopy or no
colonoscopy), solid lines
represent periods when the
strategy does not specify the
intervention (e.g., anything goes,
colonoscopy or no colonoscopy)
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detected and removed at first eligibility who were alive and
had not yet had a post-screening colonoscopy/sigmoidoscopy
or been diagnosed with colorectal cancer by z months of fol-
low-up. For each trial, individuals were classified into the
colonoscopy arm if they received a colonoscopy duringmonth
z and into the control arm otherwise.
We identified 2028 eligible individuals. On average, each
participated in 45 trials, of which at most 1 was in the colo-
noscopy arm. The number of eligible individuals who re-
ceived a colonoscopy at baseline ranged between 0 (in several
trials) and 16 (in trial z=61). See Appendix Table 3 for details.
Unfortunately, all trials had zero cancers among the exposed,
which means the data from NORCCAP cannot be used for a
meaningful emulation of trial type #1.
Trial type #1 has the advantage of being easy to emulate
and analyze when sufficient observational data are available.
This approach has been used in observational studies to esti-
mate the observational analog of the intention-to-treat effect of
statin therapy [4••] and postmenopausal hormone therapy [3].
Here, we will not consider this trial type further.
Trial type #2: sustained static strategies assigned at first
eligibility
We emulated a randomized trial with 49 arms, in which the
participants were assigned at first eligibility to colonoscopy at
a randomly assigned time ranging from month 36 to 84 after
first eligibility. Classifying the 2190 eligible individuals into a
single arm is not possible because, at baseline, each individ-
ual’s data are consistent with all 49 arms. To overcome this
problem we created an expanded dataset with 49 clones of
each individual, and assigned each of them to a different
arm [14]. The 2190 eligible subjects contributed 107,309
clones to this trial. See Appendix Table 4 for details.
The clones in the expanded dataset were censored at the
time their data deviated from the strategy to which they were
assigned. For example, in arm 84, 12.9 % of participants were
censored for having a surveillance colonoscopy too early
(before month 84), 73.5 % of participants were censored for
failing to have a surveillance colonoscopy in time (in month
84), and 0.5 % were censored for having a sigmoidoscopy.
Those who received a colonoscopy for clinical reasons or
developed malignancies other than colorectal cancer were
subsequently considered Bimmune^ from censoring.
Trial type #3: sustained dynamic strategies assigned
at first eligibility
We emulated a trial with 49 arms, one for each value of x in the
dynamic strategies defined above. The 2190 individuals were
classified into the arm that was consistent with their observed
data. Like in the previous trial, individuals cannot be assigned
to a single arm at baseline, so we created an expanded dataset
with 49 clones of each individual and assigned each of them to
a different arm. The clones were censored at the time they
deviated from the strategy to which they were assigned. For
example, in arm 84, 11.3 % of participants were censored for
having a surveillance colonoscopy too early, 79.7 % of partic-
ipants for failing to have a surveillance colonoscopy in time,
and 1.3 % for having a sigmoidoscopy. The 2190 eligible
subjects contributed 107,309 clones to this trial. See Appendix
Table 5 for details.
Emulating the Design of Hypothetical Trials
with a Grace Period
So far, we have implicitly assumed that it is possible to admin-
ister a colonoscopy at a precisely specified time point, e.g.,
month 36. However, in many clinical settings, this may not
be feasible. We may therefore be more interested in emulating
trials with a grace period, that is, a window ofmmonths during
which the patient may undergo colonoscopy. For example, in
trial type #2, patients would be assigned to interventions of the
form Bsurveillance colonoscopy between x and x+m months
after baseline.^ Trials with a grace period more accurately
reflect clinical practice in which administrative delays and
patient availability may prevent an immediate intervention.
Strategies with a grace period are emulated using Bclones^
as described above, but with different criteria for censoring.
Suppose we use a grace period ofm=6 months. An individual
who received a surveillance colonoscopy in month 40 now
has data consistent with arm 36 because subjects assigned to
this arm are allowed to have a colonoscopy at any time be-
tween months 36 and 42. Therefore, his clones assigned to
arms 36 to 40 will not be censored whereas his clones
assigned to arm 41 will be censored because he received a
surveillance colonoscopy before the assigned time.
The addition of a grace period requires us to specify the
distribution of the interventions during the grace period. For
example, we might ask whether most colonoscopies are per-
formed during the first 2 months of the grace period or wheth-
er they are more equally distributed during the grace period. In
our application, we will specify a uniform distribution of co-
lonoscopies during the grace period [14].
In both trials #2 and #3 with a 6-month grace period, each
of the 2190 eligible individuals in the original dataset contrib-
uted 49 clones, for a total of 107,310 clones to the expanded
dataset. In trial #2, the average censoring time ranged between
41.9 months for x=36 to 89.1 months for x=84. In arm 84,
12.9 % of participants were censored for having a surveillance
colonoscopy too early (before month 84), 71.5 % of partici-
pants were censored at month 90 for failing to have a surveil-
lance colonoscopy in time, 0.1 % were censored after month
90 for having a second surveillance colonoscopy, and 0.6 %
were censored for having a sigmoidoscopy. Across the 49
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arms, there were 381 incident cases of colorectal cancer in the
clones, which occurred in 12 unique individuals.
In trial #3, the average censoring time ranged from
34.2 months for x=36 to 78.1 months and for x=84. For
arm 84, 11.3 % of participants were censored for having a
surveillance colonoscopy too early, 77.6 % for failing to have
a surveillance colonoscopy in time, and 1.4 % for having a
sigmoidoscopy. In total, there were 254 incident cases of co-
lorectal cancer in 13 unique individuals. See Appendix Ta-
bles 4 and 5 for details.
Emulating the Analysis of the Hypothetical Trials
After reviewing how to create observational databases
with the same structure as hypothetical randomized trials,
we review how to use those databases to estimate the
cumulative incidence curves (or their complement, the
survival curves) that would have been observed under
each strategy if all individuals had fully adhered to their
original arm assignment. In a slight abuse of notation, we
index the strategies by the variable x, which was defined
in the previous sections. For example, in trial #2, x=78
corresponds to the strategy Bsurveillance colonoscopy
between 78 and 78+6 months after baseline.^
In a true randomized trial with many arms x, we could
estimate these curves nonparametrically (Kaplan-Meier
curves) or parametrically by fitting a pooled logistic
model of the form logitPr Y tþ1 ¼ 0jY t ¼ Dt ¼ 0; xð Þ ¼
α0;t þ α1 f xð Þ þ α2 f xð Þ  t, where t denotes time (in
months), Yt is an indicator of colorectal cancer by t, Dt is an
indicator of death by t, α0;t is a time-varying intercept (esti-
mated, for example, via restricted cubic splines for time with
knots at 30, 60, 90, and 120 months), f xð Þ is a function of x
(for example, a second degree polynomial), and f xð Þ  t is a
product term to allow the hazard ratio to vary during the fol-
low-up. For example, for the first 36 months of follow-up, the
hazard is known to be identical under all strategies, but it may
change after that if colonoscopy has a non-null effect on co-
lorectal cancer incidence.
We would then calculate the predicted values for each val-
ue of x and compute their product in order to estimate the
survival curves. Pointwise 95 % confidence intervals for the
curves can be obtained via a non-parametric bootstrap. In our
emulated trials, however, the above logistic model needs to be
adjusted by both baseline and post-baseline (time-varying)
confounders. The procedure then needs to be modified as we
now describe.
Adjustment for Covariates
In both trials # 2 and #3, we need to adjust for covariates
that jointly predict surveillance colonoscopy At (and
therefore censoring) and subsequent outcome. Some of
these variables are fixed at the baseline of each trial;
others vary during the follow-up. Let L0 represent the
vector of baseline covariates, which include age at base-
line, sex, family history of colorectal cancer, history of
smoking, and findings at NORCCAP colonoscopies
(number of adenomas, size, histology, and presence of
villous elements). Let Lt represent the vector of time-
varying covariates, which include an indicator for incident
non-colorectal malignancies, and a vector of the findings
from the most recent colonoscopy (number of adenomas,
size of largest adenoma, histological grade, and presence
of villous elements).
To adjust for L0, one could fit the pooled logistic model logit
Pr Y tþ1 ¼ 0jY t ¼ 0; x; L0ð Þ ¼ α0;t þ α1 f xð Þ þ α2 f xð Þ  tþ
α3L0 to the expanded dataset of each trial separately. To obtain
the survival curves under each strategy x, one would then cal-
culate the predicted values for each value of x, standardized
them by L0, and compute their product. However, the time-
varying covariates Lt cannot be added to the logistic model
because these variables may be affected by prior treatment
[10, 11] (a colonoscopy may change the findings at future
colonoscopies, for example by removing adenomas; see
Appendix). We therefore need to use IP weighting to adjust
for Lt.
The subject-specific, time-varying IP weights are Wt ¼
∏ j¼0t 1f A jjA j1; L j; Y j¼D j¼0ð Þ. Informally, the denominator of
the weights is each subject’s conditional probability of having,
at each time t, his or her own surveillance colonoscopy history.
We use overbars to denote history, i.e., Lt ¼ (L0, L1, L2,…, Lt).
The factors in the denominator of the weights were set to
1 in months following age 70, a non-surveillance colonos-
copy, or the diagnosis of malignancies other than colorectal
cancer because the individual has a probability 1 of remain-
ing uncensored during those months. The factors in the
denominator were also set to 1 during the first 9 months
after a colonoscopy is received, because no surveillance
colonoscopies were performed during this period (only co-
lonoscopies due to symptoms or to incompleteness of the
preceding colonoscopy). In previous applications of IP
weighting for strategies with grace periods, the investiga-
tors were interested only in strategies that were not
sustained beyond the initial decision to treat [14]. There-
fore, the contributions to the weights were set to 1 for all
time periods after treatment was first received.
For all other months, we estimate the denominator by
fitting a logistic model for the conditional probability of re-
ceiving a colonoscopy to the original, unexpanded study pop-
ulation. We fit the model
logit Pr At ¼ 1jAt−1; Lt
 
¼ β0;t þ β1g At−1
 
Pt þ β2L0 þ β3LtPt
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where β0;t is a time-varying intercept estimated via restricted
cubic splines with knots at 30, 60, 90, and 120 months, g
At1
 
is the time since the most recent colonoscopy, and
covariate history Lt is summarized via the time-varying covar-
iates Lt and the baseline variables L0, which include age (re-
stricted cubic splines with knots at 50, 55, 60, and 65 years);
sex; family history of colorectal cancer (yes/no); history of
smoking (yes/no); findings at the NORCCAP colonoscopies
(indicators for three or more adenomas, adenoma greater
than 10 mm, adenoma with villous component); and his-
tological grade (1 if high grade dysplasia, 0 otherwise).
The variables g At1
 
and Lt are entered to the model
only in a product (Binteraction^) term with Pt, an indicator
for prior colonoscopy (1 if the individual had a colonos-
copy before t, 0 otherwise), such that the terms are zero in
individuals who have not had a previous surveillance
colonoscopy.
Because the IP weights already adjusted for the baseline
covariates L0, we did not include them as covariates in
the outcome model. That is, we fit the weighted pooled logis-
tic model logit Pr Y tþ1 ¼ 0jY t ¼ 0 ; xð Þ ¼ α0;t þ α1 f xð Þþ
α2 f xð Þ  t. To check the robustness of our estimates to
different choices of functional form for time and x, we
explored different parameterizations of the outcome mod-
el, including a quadratic functional form for time, cubic
terms for x, and additional interaction terms between f(x)
and time.
Grace Period
Because our strategies of interest include grace periods, the
above-mentioned IP weights Wt need to be modified [14].
Specifically, the numerator of the factors corresponding to
months included in the grace period need to change to ensure
that surveillance colonoscopies will be uniformly distributed
during the grace period. For trial #2, the numerator of factors
corresponding to month j of the grace period is replaced by
1
mþ1 j with j=0, 1, … 5 when At=1, and replaced by
m j
mþ1 j
when At=0. For trial #3, where there can be multiple
surveillance colonoscopies, we use the same approach during
all grace periods.
Estimates from NORCCAP Data
Table 2 shows the 5- and 10-year risks of colorectal
cancer for arms 36 and 84 in trials #2 and #3. For both
static and dynamic strategies, earlier surveillance colo-
noscopy resulted in a lower risk. The estimated survival
curves for selected arms of trials #2 and #3 are shown
in Fig. 3. As expected, the survival curves are essential-
ly identical over the first 3 years, as the strategies are
the same during this time period. Results were similar
in sensitivity analyses using different functional forms
for f(x) and time.
Note that had the dataset included no cancer diagnoses
after surveillance colonoscopy, the conclusion that
delaying colonoscopy increases risk would be foregone.
In our dataset, only one individual who has a surveillance
colonoscopy between months 36 and 84 subsequently de-
veloped colorectal cancer, and he was censored before
getting cancer under most clinically relevant strategies.
Any changes to the strategies that led to him not being
censored would result in substantial changes to the esti-
mates. Therefore, our analysis needs to be replicated in a
larger dataset.
Conclusions
After a medical procedure or medication has been shown
to be effective, the next question is usually how often it
should be administered. In this paper, we reviewed an
approach that, when applied to a sufficiently large and
rich dataset, helps decide among various timing strategies.
Specifically, we outlined the design and analysis of hypo-
thetical randomized trials to compare different strategies,
and provided a methodology for emulating these trials
using observational data.
Table 2 Estimated risk of colorectal cancer at 5 and 10 years under selected surveillance strategies, intervention arm of the NORCCAP trial
Risk, % (95 % CI)
x=36
Risk, % (95 % CI)
x=84
Risk difference, %
(comparing x=36 with x=84)
(95 % CI)
Risk ratio
(comparing x=36 with x=84)
(95 % CI)
Static strategies
At 5 years 0.15 (0.03–0.37) 0.30 (0.08–0.59) −0.15 (−0.31–0.00) 0.47 (0.06–0.87)
At 10 years 0.31 (0.05– 0.69) 0.63 (0.27–1.14) −0.32 (−0.67–0.01) 0.49 (0.10–1.01)
Dynamic strategies
At 5 years 0.12 (0.00–0.36) 0.25 (0.01–0.50) −0.13 (−0.30–0.01) 0.49 (0.03–1.18)
At 10 years 0.30 (0.05–0.90) 0.44 (0.17–0.76) −0.14 (−0.46–0.03) 0.67 (0.10–1.76)
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As amotivating example, we compared the effectiveness of
different strategies for scheduling surveillance colonoscopies
in patients with adenomas, a clinical question for which the
available evidence is sparse [9, 15–20]. Our analysis suggests
that more frequent surveillance colonoscopies leads to a great-
er reduction in colorectal cancer risk; as expected, the analysis
also suggests that dynamic strategies are more effective than
static strategies. However, our analysis is more an example of
implementation than an attempt at providing definite answers
to the clinical question because the sample size of our study
was small.
The application of the methods outlined in this review
allowed us to specify a research question that is directly rele-
vant to decision makers interested in timing questions.
Though these methods allow adjustment for both baseline
and time-varying covariates, the possibility of unmeasured
confounding remains as in any observational study.
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Appendix. The Need for Inverse Probability Weights
To see why inverse probability weighting is required to adjust
for previous findings at colonoscopy, consider the directed
acyclic graph in Appendix Fig. 4. At is an indicator for colo-
noscopy at time t, Lt is an indicator for the (possibly unknown
to the investigator) presence of adenomas at time t, Lt* is an
indicator for the presence of known adenomas at time t. Ade-
nomas only become known through colonoscopy: IfAt=1 then
Lt+1*=Lt; otherwise, Lt+1*=Lt*. U represents the common
causes of adenomas and colorectal cancer, such as genetics. Y
is an indicator of colorectal cancer by the end of follow-up.
According to this causal diagram, Lt+1* is a confounder for
the effect of At+1 on Y. Knowledge of adenomas at time t+1
predicts colonoscopy at time t+1, and is also a marker for
actual adenomas Lt, which cause cancer at time k>t. However,
confounding adjustment via conditioning on the collider Lt+1*
would open the biasing path At→Lt+1*←Lt→Y. Note that, to
avoid clutter, we chose not to include the direct arrow from
At-1 (not shown on graph) to Lt, which would only increase the
number of biasing paths.
Another possible problem is that conditioning on Lt+1* may
partially block the effect of At through the path At→Lt+1*→Y.
The arrow Lt+1*→Y exists because the detection of polyps
necessarily leads to polypectomy, which affects the risk of can-
cer at later times.
Fig. 4 Causal directed acyclic graph to represent the effect of At
(colonoscopy at time t followed by polypectomy if necessary) on
colorectal cancer Y. Lt is an indicator for the presence of adenomas and
Lt* is an indicator for the presence of known adenomas at time t
Table 3 Emulation of trial type #1 (point interventions assigned at a
fixed time after first eligibility) using the control arm of the NORCCAP
randomized trial
BTrial^ Baseline
month
Eligible
individuals
Incident
cancers
Exposed
individuals
Incident
cancers
among the
exposed
1 36 2028 14 1 0
2 37 2025 14 2 0
3 38 2020 14 4 0
4 39 2013 14 3 0
5 40 2009 14 3 0
Table 3 (continued)
BTrial^ Baseline
month
Eligible
individuals
Incident
cancers
Exposed
individuals
Incident
cancers
among the
exposed
6 41 2004 14 1 0
7 42 2001 13 3 0
8 43 1995 13 3 0
9 44 1988 13 6 0
10 45 1980 13 1 0
11 46 1975 12 0 0
12 47 1971 12 1 0
13 48 1963 12 3 0
14 49 1956 12 7 0
15 50 1948 12 1 0
16 51 1945 12 2 0
17 52 1935 12 3 0
18 53 1932 12 4 0
19 54 1923 12 5 0
20 55 1916 12 3 0
21 56 1907 12 2 0
22 57 1903 12 6 0
23 58 1892 10 10 0
24 59 1876 10 4 0
25 60 1870 10 7 0
26 61 1856 10 16 0
27 62 1836 10 13 0
28 63 1818 9 10 0
29 64 1805 9 5 0
30 65 1794 9 10 0
31 66 1779 9 6 0
32 67 1768 9 8 0
33 68 1758 9 6 0
34 69 1747 9 8 0
35 70 1738 9 10 0
36 71 1725 9 3 0
37 72 1720 9 4 0
38 73 1708 9 4 0
39 74 1700 9 5 0
40 75 1690 9 4 0
41 76 1679 8 5 0
42 77 1669 8 7 0
43 78 1655 7 4 0
44 79 1647 7 4 0
45 80 1638 7 2 0
46 81 1633 7 6 0
47 82 1620 7 0 0
48 83 1617 7 4 0
49 84 1609 6 0 0
Pooled
analysis
88,156 497 228 0
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Table 5 Emulation of trial #3 (sustained strategies where the timing of colonoscopies is a function of evolving subject-specific characteristics)
Without grace period With grace period
x Participants Reached
end of
follow-up
Censored Deaths Emigration Incident
cancers
Average
time to
censoring
Reached
end of
follow-up
Censored Deaths Emigrations Incident
cancers
Average
time to
censoring
36 2189 20 2144 18 6 1 28.1 31 2122 23 10 3 34.2
37 2190 20 2142 20 7 1 29.1 31 2120 26 10 3 35.2
38 2190 20 2142 20 7 1 30.1 33 2116 28 10 3 36.2
39 2190 22 2140 20 7 1 31.1 31 2119 28 9 3 37.2
40 2190 22 2139 21 7 1 32.0 31 2118 29 9 3 38.0
41 2190 22 2139 21 7 1 33.0 33 2117 29 8 3 39.0
42 2190 24 2132 23 8 3 34.0 34 2116 29 8 3 40.0
43 2190 24 2129 26 8 3 35.0 33 2117 29 8 3 40.9
44 2190 26 2125 28 8 3 35.9 35 2113 31 8 3 41.9
45 2190 26 2125 28 8 3 36.9 34 2114 31 8 3 42.8
46 2190 27 2123 29 8 3 37.9 38 2109 32 8 3 43.8
47 2190 29 2121 29 8 3 38.8 42 2102 34 9 3 44.8
48 2190 29 2121 29 8 3 39.8 42 2101 35 9 3 45.7
49 2190 30 2120 29 8 3 40.8 41 2102 35 9 3 46.8
50 2190 30 2118 31 8 3 41.8 41 2101 36 9 3 47.8
51 2190 30 2118 31 8 3 42.7 49 2091 38 9 3 48.7
52 2190 32 2115 32 8 3 43.7 49 2087 40 9 5 49.6
53 2190 34 2110 34 9 3 44.6 49 2086 41 9 5 50.5
54 2190 34 2109 35 9 3 45.6 52 2082 42 9 5 51.5
55 2190 34 2109 35 9 3 46.6 54 2078 44 9 5 52.4
56 2190 34 2108 36 9 3 47.5 64 2067 45 9 5 53.4
57 2190 39 2101 38 9 3 48.4 63 2066 47 9 5 54.3
58 2190 40 2096 40 9 5 49.4 65 2061 49 10 5 55.2
59 2190 40 2095 41 9 5 50.3 67 2059 49 10 5 56.3
60 2190 42 2092 42 9 5 51.3 67 2059 49 10 5 57.4
61 2190 44 2088 44 9 5 52.2 70 2055 50 10 5 58.3
62 2190 46 2085 45 9 5 53.2 65 2060 50 10 5 59.2
63 2190 46 2083 47 9 5 54.1 65 2060 50 10 5 60.1
64 2190 47 2079 49 10 5 55.1 69 2055 50 10 6 61.0
65 2190 49 2077 49 10 5 56.0 71 2052 51 10 6 62.0
66 2190 49 2077 49 10 5 56.9 76 2047 51 10 6 62.8
67 2190 49 2076 50 10 5 57.8 79 2042 53 10 6 63.7
68 2190 50 2075 50 10 5 58.8 89 2026 58 11 6 64.6
69 2190 50 2075 50 10 5 59.7 95 2019 58 11 7 65.6
70 2190 50 2074 50 10 6 60.6 98 2013 61 11 7 66.6
71 2190 50 2073 51 10 6 61.5 99 2010 63 11 7 67.3
72 2190 53 2070 51 10 6 62.4 102 2006 63 12 7 68.2
73 2190 55 2067 52 10 6 63.3 107 1998 66 12 7 69.0
74 2190 61 2055 57 11 6 64.2 105 1997 68 13 7 69.8
75 2190 63 2052 57 11 7 65.1 105 1995 69 14 7 70.5
76 2190 65 2048 59 11 7 66.0 106 1992 71 14 7 71.3
77 2190 66 2046 60 11 7 66.9 108 1989 72 14 7 72.3
78 2190 68 2043 60 12 7 67.8 107 1990 72 14 7 73.1
79 2190 70 2037 64 12 7 68.6 103 1993 73 14 7 73.9
80 2190 71 2033 66 13 7 69.5 100 1995 74 14 7 74.8
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Table 5 (continued)
Without grace period With grace period
x Participants Reached
end of
follow-up
Censored Deaths Emigration Incident
cancers
Average
time to
censoring
Reached
end of
follow-up
Censored Deaths Emigrations Incident
cancers
Average
time to
censoring
81 2190 74 2028 67 14 7 70.4 104 1991 74 14 7 75.6
82 2190 76 2023 70 14 7 71.2 105 1988 75 14 8 76.5
83 2190 76 2021 72 14 7 72.1 103 1986 79 14 8 77.2
84 2190 76 2021 72 14 7 73.0 107 1978 82 14 9 78.1
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